[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20161443A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
PE20161443A1
PE20161443A1 PE2016001250A PE2016001250A PE20161443A1 PE 20161443 A1 PE20161443 A1 PE 20161443A1 PE 2016001250 A PE2016001250 A PE 2016001250A PE 2016001250 A PE2016001250 A PE 2016001250A PE 20161443 A1 PE20161443 A1 PE 20161443A1
Authority
PE
Peru
Prior art keywords
optionally substituted
alcoxyl
cycloalkyl
disease
methyl
Prior art date
Application number
PE2016001250A
Other languages
English (en)
Inventor
Colin Michael Edge
Xiao Ding
Qian Liu
Zehong Wan
Baowei Zhao
Yingxia Sang
Luigi Piero Stasi
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20161443A1 publication Critical patent/PE20161443A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOL DE FORMULA (I) DONDE R1 ES H, ALCOXILO C1-C3, ALQUILO C1-C3 O HALO; R2 ES ALQUILO C1-C5 OPCIONALMENTE SUSTITUIDO O -(CRaRb)n-Y, EN DONDE n ES 0, 1 O 2; Ra Y Rb SON CADA UNO H O METILO; Y ES HETEROCICLILO DE 4 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO, CICLOALQUILO C3-C6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; R3 ES H, ALCOXILO C1-C3, ENTRE OTROS; R4 ES CH O N; R5 ES H, CN O METILO; R6 ES ALCOXI C1-C3 O -O-CH2-CICLOALQUILO C3-C6. ES UN COMPUESTO PREFERIDO (R)-N-(5-CLORO-1-(3,3-DIFLUORO-1-(OXETAN-3-IL)PIPERIDIN-4-IL)-1H-PIRAZOL-4-IL)-4-ETOXI-7H-PIRROLO[2,3-d]PIRIMIDIN-2-AMINA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LAS CINASAS LRRK2 SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, ENFERMEDAD DE ALZHEIMER
PE2016001250A 2014-01-29 2015-01-28 Compuestos PE20161443A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014000139 2014-01-29

Publications (1)

Publication Number Publication Date
PE20161443A1 true PE20161443A1 (es) 2017-01-06

Family

ID=53756224

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001250A PE20161443A1 (es) 2014-01-29 2015-01-28 Compuestos

Country Status (20)

Country Link
US (2) US10087186B2 (es)
EP (1) EP3099695B1 (es)
JP (1) JP6422986B2 (es)
KR (1) KR20160106622A (es)
CN (1) CN105940004B (es)
AU (2) AU2015210593A1 (es)
CA (1) CA2937431A1 (es)
CL (1) CL2016001895A1 (es)
CR (1) CR20160348A (es)
DO (2) DOP2016000195A (es)
EA (1) EA029774B1 (es)
ES (1) ES2802174T3 (es)
IL (1) IL246579B (es)
MA (1) MA39219B1 (es)
MX (1) MX367370B (es)
PE (1) PE20161443A1 (es)
PH (1) PH12016501307A1 (es)
SG (1) SG11201605342UA (es)
UA (1) UA118369C2 (es)
WO (1) WO2015113452A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10339791B2 (en) 2007-06-12 2019-07-02 Icontrol Networks, Inc. Security network integrated with premise security system
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
EA029774B1 (ru) 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
CN105153131B (zh) * 2015-09-21 2017-10-17 马彦丽 一种在护理上治疗人神经胶质瘤的药物组合物
CN105348270B (zh) * 2015-11-09 2018-01-09 吕显艳 一种防治牙体牙髓感染的药物组合物
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
EP3389663A4 (en) 2015-12-16 2019-07-03 Southern Research Institute PYRROLOPYRIMIDINE COMPOUNDS, USE AS LACKERS OF THE LRRK2 KINASE AND METHOD FOR THE PRODUCTION THEREOF
CN105418616B (zh) * 2015-12-26 2018-01-12 山东大学 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
BR112019015278A2 (pt) * 2017-01-25 2020-04-14 Glaxosmithkline Ip Dev Ltd compostos
WO2018155916A2 (ko) * 2017-02-22 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
PT3604304T (pt) * 2017-03-23 2022-11-30 Korea Res Inst Bioscience & Biotechnology Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase
KR20200085779A (ko) 2017-12-05 2020-07-15 주식회사 오스코텍 Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
WO2020036437A1 (ko) * 2018-08-16 2020-02-20 재단법인 대구경북첨단의료산업진흥재단 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
AU2019350717A1 (en) * 2018-09-25 2021-05-27 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
CZ308800B6 (cs) * 2019-02-12 2021-05-26 Univerzita Palackého v Olomouci Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci
AU2021371697B2 (en) * 2020-10-29 2024-10-24 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
WO2024056775A1 (en) 2022-09-15 2024-03-21 H. Lundbeck A/S Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504243A (ja) 2003-09-03 2007-03-01 ニューロジェン・コーポレーション 5−アリール−ピラゾロ[4,3−d]ピリミジン類、ピリジン類、ピラジン類及び関連化合物
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8029986B2 (en) 2004-10-21 2011-10-04 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
BRPI0617241A2 (pt) 2005-10-13 2016-11-08 Glaxo Group Ltd composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143404A1 (en) 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
KR20120081609A (ko) * 2009-09-29 2012-07-19 글락소 그룹 리미티드 신규 화합물
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
RS56583B1 (sr) * 2010-11-10 2018-02-28 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ1δ(CK1δ)阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
CA2831634C (en) 2011-04-21 2019-11-12 Origenis Gmbh Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors
CN103814030A (zh) 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
BR112014012822A8 (pt) * 2011-11-30 2017-07-11 Hoffmann La Roche Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
GB201204985D0 (en) * 2012-03-21 2012-05-02 Genentech Inc Compounds
CN106279202A (zh) 2012-05-03 2017-01-04 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物
JP6218808B2 (ja) 2012-05-03 2017-10-25 ジェネンテック, インコーポレイテッド Lrrk2モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
ES2637245T3 (es) * 2012-06-29 2017-10-11 Pfizer Inc. Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2
EA029774B1 (ru) 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds

Also Published As

Publication number Publication date
PH12016501307B1 (en) 2016-08-15
US10618901B2 (en) 2020-04-14
CR20160348A (es) 2017-04-28
MX2016009893A (es) 2016-10-31
WO2015113452A1 (en) 2015-08-06
SG11201605342UA (en) 2016-08-30
EP3099695A4 (en) 2017-07-12
MX367370B (es) 2019-08-16
US20180354956A1 (en) 2018-12-13
MA39219B1 (fr) 2018-11-30
JP6422986B2 (ja) 2018-11-14
CN105940004A (zh) 2016-09-14
CA2937431A1 (en) 2015-08-06
JP2017504631A (ja) 2017-02-09
US10087186B2 (en) 2018-10-02
DOP2016000195A (es) 2016-10-31
CN105940004B (zh) 2018-02-02
ES2802174T3 (es) 2021-01-15
EA029774B1 (ru) 2018-05-31
UA118369C2 (uk) 2019-01-10
AU2018200277A1 (en) 2018-02-01
AU2018200277B2 (en) 2019-09-26
DOP2019000010A (es) 2019-03-15
EP3099695A1 (en) 2016-12-07
CL2016001895A1 (es) 2016-12-09
AU2015210593A1 (en) 2016-07-07
MA39219A1 (fr) 2017-09-29
EP3099695B1 (en) 2020-04-08
PH12016501307A1 (en) 2016-08-15
EA201691514A1 (ru) 2016-12-30
IL246579B (en) 2019-05-30
KR20160106622A (ko) 2016-09-12
US20170015668A1 (en) 2017-01-19
IL246579A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
PE20161443A1 (es) Compuestos
PE20191540A1 (es) DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA
NZ732657A (en) Picolinamides with fungicidal activity and other related compounds
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20141974A1 (es) Compuestos de heterociclilo
PH12016501440A1 (en) Novel heterocyclic compounds
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
PE20171737A1 (es) Derivados de quinazolinona biciclicos
PE20160992A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk)
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
PE20142164A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida